Skip to main content

Aptevo Therapeutics (US:APVO) — Company Overview, News & Financial Data

Aptevo Therapeutics logo
APVOAptevo Therapeutics
Aptevo Therapeutics primary media
Company profile

About Aptevo Therapeutics

Aptevo Therapeutics (NASDAQ:APVO) is a biotechnology company focused on developing novel oncology and hematology treatments. They are driven by innovation in the field of protein engineering to create therapies that aim to improve patients' lives. Aptevo’s operations span from early-stage discovery and development to the clinical trial phase, with a strategic emphasis on targeted therapies that address unmet medical needs. Among its projects, the company is known for pioneering platforms that enable the generation of therapeutic candidates with improved pharmacological properties. A key objective for Aptevo is to advance its pipeline of innovative candidates through the development stages efficiently, aiming to bring breakthrough treatments to the market. Their work exemplifies a commitment to leveraging scientific insights for the development of life-saving and life-altering therapies.

Snapshot

Public USOwnership
2016Year founded
40Employees
Seattle, United StatesHead office
Loading Map...
Global footprint

Operations

All Locations
Seattle, US

Products and/or services of Aptevo Therapeutics

  • APVO436: A bispecific antibody targeting CD123 and CD3 for acute myeloid leukemia and myelodysplastic syndrome.
  • APVO603: A dual agonist bispecific antibody to costimulate T cells for cancer treatment.
  • APVO210: A bispecific antibody designed to modulate the costimulatory signal for autoimmune diseases.
  • ALG.APV-527: A bispecific antibody targeting 4-1BB and 5T4 antigens for solid tumors.
  • RAPA-201-301: A Phase 1/2 trial for APVO436 in acute myeloid leukemia and high-grade myelodysplastic syndrome.
  • XmAb®14045: A collaboration on an XmAb bispecific antibody for CD123-positive hematologic malignancies.

Aptevo Therapeutics executive team

  • Mr. Marvin L. WhitePresident, CEO & Director
  • Mr. Jeffrey G. Lamothe CAExecutive VP & COO
  • Ms. SoYoung Kwon J.D., LL.M.Corporate Secretary, Senior VP, General Counsel, Business Development & Corporate Affairs
  • Ms. Daphne L. Taylor CPASenior VP & CFO
  • Dr. Dirk Huebner M.D.Chief Medical Officer